References

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

10.1038/nrd4010 · 2013 · External reference

Unraveling resistance mechanisms to the novel nucleoside analog RX-3117 in lung cancer: insights into DNA repair, cell cycle dysregulation and targeting PKMYT1 for improved therapy

10.1186/s13046-025-03470-z · 2025 · External reference

AP1M2 Drives Gemcitabine‐Cisplatin Chemoresistance by Enhancing RAD54B‐Associated DNA Repair in Bladder Cancer

10.1096/fj.202500423r · 2025 · External reference

Epigenetic Drivers of Chemoresistance in Nucleobase and Nucleoside Analog Therapies

10.3390/biology14070838 · 2025 · External reference

Epigenetic Biomarkers for predicting Nucleoside Analog Drug Response and Resistance in Cancer

10.3390/biom16040587 · 2026 · External reference

Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets

10.1038/s41392-023-01480-x · 2023 · External reference

Exploring viral mimicry combined with epigenetics and tumor immunity: new perspectives in cancer therapy

10.7150/ijbs.103877 · 2025 · External reference

Advanced prodrug strategies in nucleoside analogues targeting the treatment of gastrointestinal malignancies

10.3389/fcell.2023.1173432 · 2023 · External reference

Advancing Epigenetic Combination Therapy in Oncology: Multifunctional Nano-Drug delivery Systems for Synergistic Efficacy and Precision Modulation

2025 · External reference

The Role of SAMHD1 in Viral Resistance and Transduction Efficiency challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives

2025 · External reference

Unresolved reference

2025 · External reference

Microbial metabolites in tumor metabolic reprogramming and immunotherapy: new insights

10.3389/fcimb.2025.1706040 · 2025 · External reference

Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer

10.3389/fphar.2024.1510851 · 2025 · External reference

Current and emerging prodrug strategies

10.1021/acs.jmedchem.5c00826 · 2025 · External reference

Prodrug-based drug delivery systems: strategic approaches and emerging challenges in targeted therapeutics

2025 · External reference

The ProTide Prodrug Technology: from the Concept to the Clinic: Miniperspective

10.1021/acs.jmedchem.7b00734 · 2017 · External reference

Is monitoring of the intracellular active metabolite levels of nucleobase and nucleoside analogs ready for precision medicine applications?

10.1007/s13318-022-00786-5 · 2022 · External reference

Cell and tissue specific metabolism of nucleoside and nucleotide drugs: case studies and implications for precision medicine

10.1124/dmd.122.000856 · 2023 · External reference

Clinical translation of Self‐Assembled cancer nanomedicines

2021 · External reference

Prodrug-based combinational nanomedicine remodels lipid metabolism for reinforced ferroptosis and immune activation

10.1016/j.apsb.2025.03.016 · 2025 · External reference

Is it still worth renewing nucleoside anticancer drugs nowadays?

10.1016/j.ejmech.2023.115987 · 2024 · External reference

A general nanoplatform for nucleotide drug delivery: from molecular binding to antiviral therapy

2025 · External reference

Application of artificial intelligence in drug discovery

10.2174/1381612828666220608141049 · 2022 · External reference

Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs

10.1021/acs.chemrev.6b00209 · 2016 · External reference

Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy

10.1186/s13045-022-01263-x · 2022 · External reference

Nucleoside-based anticancer drugs: Mechanism of action and drug resistance

10.1016/j.bcp.2023.115741 · 2023 · External reference

Emerging roles of nucleotide metabolism in cancer

10.1016/j.trecan.2023.04.008 · 2023 · External reference

Nucleosides with fluorinated nucleobases for antiviral and anticancer therapies

10.1016/j.fmre.2025.06.002 · 2025 · External reference

Enhancing the Nucleoside Analog Response with Translational Therapeutic Approaches to Overcome Resistance

10.3390/cells15020130 · 2026 · External reference

5-fluorouracil: mechanisms of action and clinical strategies

10.1038/nrc1074 · 2003 · External reference

Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells

2009 · External reference

APOBEC3 upregulation drives gemcitabine resistance

10.1038/s43018-024-00755-8 · 2024 · External reference

A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability

10.1038/s41401-019-0227-7 · 2019 · External reference

Unlocking the potential of cytarabine: a comprehensive review from molecular insights to advanced nanoformulations and Co-delivery strategies for enhanced drug efficacy

10.1016/j.jddst.2024.106346 · 2024 · External reference

Gemcitabine alters phosphatidylcholine metabolism in mouse pancreatic tumors

10.1021/acs.jproteome.4c00839 · 2025 · External reference

Recent progress in gemcitabine-loaded nanoparticles for pancreatic cancer therapy: a review

10.1039/d5nr02005k · 2025 · External reference

Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells

10.3389/fphar.2023.1134895 · 2023 · External reference

Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer

10.1021/cr900028p · 2009 · External reference

DNA replication stress induced by trifluridine determines tumor cell fate according to p53 status

10.1158/1541-7786.mcr-19-1051 · 2020 · External reference

TAS-102, a novel antitumor agent: a review of the mechanism of action

10.1016/j.ctrv.2015.06.001 · 2015 · External reference

5-fluorouracil and other fluoropyrimidines in colorectal cancer

2020 · External reference

Xianglian Pill combined with 5-fluorouracil enhances antitumor activity and reduces gastrointestinal toxicity in gastric cancer by regulating the p38 MAPK/NF-κB signaling pathway

10.1016/j.jep.2024.117988 · 2024 · External reference

Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance

10.1038/s41467-021-27847-8 · 2022 · External reference

Inhibitors of the cancer target ribonucleotide reductase, past and present

10.3390/biom12060815 · 2022 · External reference

Preclinical Toxicology of Antimetabolite Drugs used in Cancer Therapy–Literary Review

2024 · External reference

Cellular responses to widespread DNA replication stress

10.3390/ijms242316903 · 2023 · External reference

DNA methylation, methyltransferases, and cancer

10.1038/sj.onc.1204341 · 2001 · External reference

Recent progress in DNA methyltransferase inhibitors as anticancer agents

10.3389/fphar.2022.1072651 · 2022 · External reference

Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment

10.1016/j.celrep.2023.113098 · 2023 · External reference

Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression

10.3389/fphar.2022.991751 · 2022 · External reference

DNA hypomethylating drugs in cancer therapy

10.1101/cshperspect.a026948 · 2017 · External reference

DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability

10.1038/s41388-022-02404-9 · 2022 · External reference

Unresolved reference

2022 · External reference

DNMT inhibition epigenetically restores the cGAS-STING pathway and activates RIG-I/MDA5-MAVS to enhance antitumor immunity

10.1038/s41401-025-01639-y · 2026 · External reference

Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma

10.1158/2159-8290.cd-25-0587 · 2025 · External reference

Nucleoside-based anticancer drugs: Mechanism of action and drug resistance

10.1016/j.bcp.2023.115741 · 2023 · External reference

Nucleoside analogs: molecular mechanisms signaling cell death

10.1038/onc.2008.316 · 2008 · External reference

Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism

10.3390/cancers10070240 · 2018 · External reference

Drug resistance in cancer: molecular mechanisms and emerging treatment strategies

10.1186/s43556-025-00352-w · 2025 · External reference

Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming

2025 · External reference

Nanomedicines for overcoming cancer drug resistance

10.3390/pharmaceutics14081606 · 2022 · External reference

Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy‐naïve pT2 gallbladder adenocarcinoma patients

10.1111/his.12805 · 2016 · External reference

Role of human nucleoside transporters in pancreatic cancer and chemoresistance

10.3748/wjg.v27.i40.6844 · 2021 · External reference

“Open Sesame?”: Biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and cytotoxicity of gemcitabine in pancreatic cancer

10.3390/cancers12113206 · 2020 · External reference

hENT1 expression predicts response to gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma

10.1158/1078-0432.ccr-22-2576 · 2022 · External reference

Elucidation of the gemcitabine transporters of escherichia coli K-12 and gamma-proteobacteria linked to gemcitabine-related chemoresistance

10.3390/ijms25137012 · 2024 · External reference

Nanoparticle-based delivery strategies for combating drug resistance in cancer therapeutics

10.3390/cancers17162628 · 2025 · External reference

MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells

10.1016/j.bbamcr.2020.118824 · 2020 · External reference

Multidrug resistance protein 5 affects cell proliferation, migration and gemcitabine sensitivity in pancreatic cancer MIA Paca‑2 and PANC‑1 cells

10.3892/or.2023.8666 · 2023 · External reference

Unresolved reference

2025 · External reference

The role of various collagen types in tumor biology: a review

2025 · External reference

Collagen Signaling via DDR1 Exacerbates Barriers to Macromolecular Drug delivery in a 3D Model of Pancreatic Cancer Fibrosis

10.1002/smll.202506926 · 2025 · External reference

Decitabine/cedazuridine: first approval

10.1007/s40265-020-01389-7 · 2020 · External reference

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

10.1016/s2352-3026(23)00338-1 · 2024 · External reference

FDA approval summary: decitabine and cedazuridine tablets for myelodysplastic syndromes

10.1158/1078-0432.ccr-21-4498 · 2022 · External reference

Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel

10.1016/j.isci.2024.108907 · 2024 · External reference

The N-terminal SAM domain of the dNTPase SAMHD1 is not required for inhibition by small molecule TH6342

10.1080/15257770.2024.2325439 · 2024 · External reference

Deoxyguanosine-Linked Bifunctional Inhibitor of SAMHD1 dNTPase activity and Nucleic Acid Binding

10.1021/acschembio.3c00118 · 2023 · External reference

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies

10.1038/nm.4265 · 2017 · External reference

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses

10.1038/s41392-025-02523-1 · 2025 · External reference

Precision medicine engaging nucleoside analogues: New advances to a conventional arsenal

10.1007/s13596-024-00747-0 · 2025 · External reference

Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology

10.1038/s41467-017-01582-5 · 2017 · External reference

Clinical use of biomarkers in the field of cytotoxic nucleoside analogues

10.1080/15257770.2023.2272640 · 2024 · External reference

Epigenetic changes in nucleoside transporter hENT1 and dCK, as mechanism for gemcitabine-aquired resistance in cervical cancer cell lines

10.1200/jco.2010.28.15_suppl.e13633 · 2010 · External reference

Acquired Resistance to Decitabine Associated with the Deoxycytidine Kinase A180P Mutation: Implications for the Order of Hypomethylating Agents in Myeloid Malignancies Treatment

10.3390/ijms26115083 · 2025 · External reference

Structure of human dCK suggests strategies to improve anticancer and antiviral therapy

10.1038/nsb942 · 2003 · External reference

Development and preclinical pharmacology of a novel dCK inhibitor, DI-87

10.1016/j.bcp.2019.113742 · 2020 · External reference

Ribonucleotide reductases: structure, chemistry, and metabolism suggest new therapeutic targets

10.1146/annurev-biochem-013118-111843 · 2020 · External reference

Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies

10.1038/onc.2014.155 · 2015 · External reference

mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer

10.1016/j.neo.2021.05.007 · 2021 · External reference

Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment

10.3390/cancers13164200 · 2021 · External reference

Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients

10.1007/s00280-023-04579-8 · 2023 · External reference

Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery

10.1007/s10637-024-01455-x · 2024 · External reference

Structure of human cytidine deaminase bound to a potent inhibitor

10.1021/jm0496279 · 2005 · External reference

The Emerging Role of Cytidine Deaminase in Human Diseases: a New Opportunity for Therapy?

10.1016/j.ymthe.2019.11.026 · 2020 · External reference

Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase

10.1038/onc.2013.357 · 2014 · External reference

Cytidine Deaminase Resolves Replicative stress and Protects Pancreatic Cancer from DNA-Targeting Drugs

10.1158/0008-5472.can-22-3219 · 2024 · External reference

Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML

10.1038/s41419-022-05023-0 · 2022 · External reference

Structural insight into dGTP-dependent activation of tetrameric SAMHD1 deoxynucleoside triphosphate triphosphohydrolase

10.1038/ncomms3722 · 2013 · External reference

GTP activator and dNTP substrates of HIV-1 restriction factor SAMHD1 generate a long-lived activated state

10.1073/pnas.1401706111 · 2014 · External reference

Platform-directed allostery and quaternary structure dynamics of SAMHD1 catalysis

10.1038/s41467-024-48237-w · 2024 · External reference

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

10.1038/nm.4255 · 2017 · External reference

The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1

10.1073/pnas.1805593115 · 2018 · External reference

Targeting the DNA damage response and repair in cancer through nucleotide metabolism

10.1002/1878-0261.13227 · 2022 · External reference

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies

10.1038/nm.4265 · 2017 · External reference

Mre11 exonuclease activity removes the chain-terminating nucleoside analog gemcitabine from the nascent strand during DNA replication

2020 · External reference

Targeting WEE1 kinase in gynecological malignancies

10.2147/dddt.s462056 · 2024 · External reference

dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells

10.1111/cas.14718 · 2021 · External reference

Replication stress in Cancer: Mechanistic Insights and Therapeutic Opportunities for Radiosensitization

10.3390/cimb48010067 · 2026 · External reference

Overcoming Microbiome-acquired gemcitabine resistance in pancreatic ductal adenocarcinoma

10.3390/biomedicines12010227 · 2024 · External reference

Microbiota and their metabolites potentiate cancer immunotherapy: Therapeutic target or resource for small molecule drug discovery?

10.3389/fphar.2022.1091124 · 2022 · External reference

Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer

10.1186/s13046-018-0985-y · 2019 · External reference

Fecal microbiota transplantation augments 5-fluorouracil efficacy in pancreatic cancer via gut microbiota modulation

2025 · External reference

Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: phase 2 results from the NuTide: 701 study

10.1158/1535-7163.targ-23-c032 · 2023 · External reference

Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

10.20517/cdr.2022.136 · 2023 · External reference

Problems related to resistance to cytarabine in acute myeloid leukemia

10.1080/1042819032000159861 · 2004 · External reference

Drug resistance to cytotoxic nucleoside analogues

10.2174/1389450033490957 · 2003 · External reference

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies

10.1038/s41375-021-01218-0 · 2021 · External reference

Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors

10.1016/j.beha.2023.101521 · 2023 · External reference

Review of transporter substrate, inhibitor, and inducer characteristics of cladribine

10.1007/s40262-021-01065-3 · 2021 · External reference

Cellular pharmacology of fludarabine: molecular determinants of transport and metabolism

10.3389/fphar.2026.1818501 · 2026 · External reference

Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action

10.1038/s41375-025-02529-2 · 2025 · External reference

Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer

10.3748/wjg.v31.i29.109947 · 2025 · External reference

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

10.3892/or.2014.3487 · 2014 · External reference

Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer

10.1056/nejmoa2214963 · 2023 · External reference

10.1016/j.clcc.2024.12.002

10.1016/j.clcc.2024.12.002 · External reference

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia

10.1038/sj.bjc.6602881 · 2005 · External reference

The Role of CPX-351 in the Acute Myeloid Leukemia Treatment Landscape: Mechanism of Action, Efficacy, and Safety: L. Pagano et al

10.1007/s40265-025-02194-w · 2025 · External reference

The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX‐351) in Acute Myeloid Leukemia patients: a Systematic Review

10.1002/cnr2.70199 · 2025 · External reference

CPX-351: from preclinical studies to future directions

2026 · External reference

Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers

10.3390/cancers13050966 · 2021 · External reference

Quality-adjusted Time without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7+ 3 in older adults with newly diagnosed high-risk/secondary AML

10.1186/s13045-021-01119-w · 2021 · External reference

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5: 1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia

10.1200/jco.2010.30.5961 · 2011 · External reference

Transplant outcomes after CPX-351 vs 7+ 3 in older adults with newly diagnosed high-risk and/or secondary AML

10.1182/bloodadvances.2021006468 · 2022 · External reference

Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development

10.1021/jm401853a · 2014 · External reference

Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells

10.1593/neo.10576 · 2010 · External reference

NUC-3373 targets the DNA-directed pathway more effectively than 5-FU

10.1158/1538-7445.am2022-1835 · 2022 · External reference

O-2 phase III study of NUC-1031+ cisplatin vs gemcitabine+ cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide: 121)

10.1016/j.annonc.2023.04.017 · 2023 · External reference

A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer

10.1016/j.jhep.2025.01.040 · 2025 · External reference

NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials

10.1007/s12032-020-01386-6 · 2020 · External reference

A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide: 302)

10.1200/jco.2021.39.3_suppl.93 · 2021 · External reference

The novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human phase I clinical trial

10.1158/1078-0432.ccr-21-1652 · 2021 · External reference

Unresolved reference

2022 · External reference

455MO NUC-7738 in patients with advanced solid tumours: phase I results from the NuTide: 701 phase I/II study

10.1016/j.annonc.2022.07.584 · 2022 · External reference

1530P Patient derived organoids reveal synergy between NUC-7738 and PD-1 inhibition in renal cell carcer

10.1016/j.annonc.2025.08.2161 · 2025 · External reference

“Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer

10.3390/cancers12113206 · 2020 · External reference

Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping

10.1002/cpt.2667 · 2022 · External reference

Fluoropyrimidine Dosage and Toxicity

2025 · External reference

Enhanced stability and efficacy of GEM-TOS prodrug by co-assembly with antimetastatic shell LMWH-TOS

10.1016/j.apsb.2019.06.008 · 2020 · External reference

Membrane‐permeable triphosphate prodrugs of nucleoside analogues

10.1002/anie.201511808 · 2016 · External reference

Innovative nanomedicine delivery: targeting tumor microenvironment to defeat drug resistance

10.3390/pharmaceutics16121549 · 2024 · External reference

Advancements in pH-responsive nanocarriers: enhancing drug delivery for tumor therapy

10.1080/17425247.2023.2292678 · 2023 · External reference

Antibody–drug conjugates: recent advances in payloads

10.1016/j.apsb.2023.06.015 · 2023 · External reference

Novel telomere-targeting dual-pharmacophore dinucleotide prodrugs for anticancer therapy

10.1093/nar/gkaf591 · 2025 · External reference

Chemotherapeutic Spherical Nucleic Acids

10.1021/acsnano.5c16609 · 2025 · External reference

Design, synthesis, and antitumor activity of novel thioheterocyclic nucleoside derivatives by suppressing the c-MYC pathway

10.1016/j.apsb.2025.05.008 · 2025 · External reference

N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer

10.1016/j.jconrel.2018.03.013 · 2018 · External reference

CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape

10.1016/j.ijpharm.2019.118518 · 2019 · External reference

Co-administration of iRGD enhances tumor-targeted delivery and anti-tumor effects of paclitaxel-loaded PLGA nanoparticles for colorectal cancer treatment

10.1201/9780429065767 · 2019 · External reference

Self-assembled lipid–prodrug nanoparticles

10.1038/s44222-023-00082-0 · 2023 · External reference

Orally delivered berberine derivatives for dual therapy in diabetic complications with MRSA infections

10.1016/j.cclet.2024.109917 · 2025 · External reference

Gemcitabine and Pin1 siRNA co-delivery with fucoidan-coated nano-liposomes for therapy of pancreatic cancer

10.1016/j.jddst.2023.104872 · 2023 · External reference

Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation

10.1186/s12943-025-02325-7 · 2025 · External reference

Unresolved reference

2025 · External reference

Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis

10.1016/j.apsb.2023.03.004 · 2023 · External reference

A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin’s lymphoma

10.1186/s12951-024-02745-5 · 2024 · External reference

Nanoassemblies from amphiphilic cytarabine prodrug for leukemia targeted therapy

10.1016/j.jcis.2016.10.041 · 2017 · External reference

Collagenase-functionalized liposomes overcome stromal barriers in pancreatic cancer

10.1021/acsnano.5c20618 · 2026 · External reference

Cascade‐Targeted Nanoparticles for Enhanced Gemcitabine delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer

10.1002/advs.202507118 · 2025 · External reference

FU-coating pH-sensitive liposomes for improving the release of gemcitabine by endosome escape in pancreatic cancer cells

10.1016/j.jddst.2022.104135 · 2023 · External reference

Rational formulation and industrial manufacturing of lipid-based complex injectables: Landmarks and trends

10.1016/j.jconrel.2024.07.021 · 2024 · External reference

Barrier permeation and improved nanomedicine delivery in tumor microenvironments

10.1016/j.canlet.2023.216166 · 2023 · External reference

Supramolecular nanomedicine in the intelligent cancer therapy: recent advances and future

2024 · External reference

Unresolved reference

2020 · External reference

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer

10.1158/2159-8290.cd-11-0242 · 2012 · External reference

Reverse intratumor bacteria-induced gemcitabine resistance with carbon nanozymes for enhanced tumor catalytic-chemo therapy

10.1016/j.nantod.2022.101395 · 2022 · External reference

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

10.1186/s12935-023-03057-8 · 2023 · External reference

Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer

10.1016/j.biopha.2023.115389 · 2023 · External reference

A phase I/II trial of oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer

10.1158/1078-0432.ccr-22-2074 · 2023 · External reference

A polymeric nanovesicle delivers sulfopin and gemcitabine to remodel tumor microenvironment for enhanced chemoimmunotherapy against orthotopic pancreatic cancer

2025 · External reference

Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma

10.1186/s12943-020-01297-0 · 2021 · External reference

5-FU@ HFn combined with decitabine induces pyroptosis and enhances antitumor immunotherapy for chronic myeloid leukemia

10.1186/s12951-025-03335-9 · 2025 · External reference

Macrophage membrane-coated nano-gemcitabine promotes lymphocyte infiltration and synergizes AntiPD-L1 to restore the tumoricidal function

10.1021/acsnano.2c07861 · 2022 · External reference

Targeting PD‐L1 with DNA Aptamers and Conjugated with Gemcitabine as a Novel Therapeutic Strategy for Bladder Cancer Chemotherapy combined with Immunotherapy

10.1002/smsc.202370023 · 2023 · External reference

Transformer-based Molecular Generative Model for Antiviral Drug Design

10.1021/acs.jcim.3c00536 · 2024 · External reference

Transfer learning with multiomics integration and deep neural networks reveals drug resistance mechanisms in cancer

10.1038/s41598-025-23435-8 · 2025 · External reference

Clinical application and drug resistance mechanism of gemcitabine

10.3389/fcell.2025.1702720 · 2025 · External reference